Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 2
1969 2
1970 1
1972 1
1973 2
1974 1
1975 3
1976 6
1977 1
1978 2
1979 3
1980 3
1981 4
1982 4
1983 8
1984 5
1985 12
1986 19
1987 13
1988 7
1989 10
1990 22
1991 17
1992 27
1993 21
1994 29
1995 18
1996 26
1997 25
1998 19
1999 31
2000 35
2001 22
2002 31
2003 44
2004 38
2005 24
2006 45
2007 42
2008 48
2009 33
2010 26
2011 30
2012 23
2013 21
2014 25
2015 20
2016 17
2017 17
2018 12
2019 11
2020 10
2021 10
2022 16
2023 7
2024 10
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

915 results

Results by year

Filters applied: . Clear all
Page 1
Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study.
Ortiz M, Martín A, Arribas F, Coll-Vinent B, Del Arco C, Peinado R, Almendral J; PROCAMIO Study Investigators. Ortiz M, et al. Eur Heart J. 2017 May 1;38(17):1329-1335. doi: 10.1093/eurheartj/ehw230. Eur Heart J. 2017. PMID: 27354046 Free PMC article. Clinical Trial.
AIMS: Intravenous procainamide and amiodarone are drugs of choice for well-tolerated ventricular tachycardia. However, the choice between them, even according to Guidelines, is unclear. ...Tachycardia terminated within 40 min in 22 (67%) procainamide and 11 (38%) amioda
AIMS: Intravenous procainamide and amiodarone are drugs of choice for well-tolerated ventricular tachycardia. However, the choice bet …
A randomized clinical trial of catheter ablation and antiarrhythmic drug therapy for suppression of ventricular tachycardia in ischemic cardiomyopathy: The VANISH2 trial.
Sapp JL, Tang ASL, Parkash R, Stevenson WG, Healey JS, Wells G. Sapp JL, et al. Am Heart J. 2024 Aug;274:1-10. doi: 10.1016/j.ahj.2024.04.009. Epub 2024 Apr 21. Am Heart J. 2024. PMID: 38649085 Clinical Trial.
Enrolled patients are classified as either sotalol-eligible, or amiodarone-eligible, and then are randomized to either catheter ablation or to that antiarrhythmic drug therapy, with randomization stratified by drug-eligibility group. ...
Enrolled patients are classified as either sotalol-eligible, or amiodarone-eligible, and then are randomized to either catheter ablat …
Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest.
Kudenchuk PJ, Brown SP, Daya M, Rea T, Nichol G, Morrison LJ, Leroux B, Vaillancourt C, Wittwer L, Callaway CW, Christenson J, Egan D, Ornato JP, Weisfeldt ML, Stiell IG, Idris AH, Aufderheide TP, Dunford JV, Colella MR, Vilke GM, Brienza AM, Desvigne-Nickens P, Gray PC, Gray R, Seals N, Straight R, Dorian P; Resuscitation Outcomes Consortium Investigators. Kudenchuk PJ, et al. N Engl J Med. 2016 May 5;374(18):1711-22. doi: 10.1056/NEJMoa1514204. Epub 2016 Apr 4. N Engl J Med. 2016. PMID: 27043165 Free article. Clinical Trial.
RESULTS: In the per-protocol population, 3026 patients were randomly assigned to amiodarone (974), lidocaine (993), or placebo (1059); of those, 24.4%, 23.7%, and 21.0%, respectively, survived to hospital discharge. The difference in survival rate for amiodarone ver …
RESULTS: In the per-protocol population, 3026 patients were randomly assigned to amiodarone (974), lidocaine (993), or placebo (1059) …
Propafenone versus amiodarone for supraventricular arrhythmias in septic shock: a randomised controlled trial.
Balik M, Maly M, Brozek T, Rulisek J, Porizka M, Sachl R, Otahal M, Brestovansky P, Svobodova E, Flaksa M, Stach Z, Horejsek J, Volny L, Jurisinova I, Novotny A, Trachta P, Kunstyr J, Kopecky P, Tencer T, Pazout J, Belohlavek J, Duska F, Krajcova A, Waldauf P. Balik M, et al. Intensive Care Med. 2023 Nov;49(11):1283-1292. doi: 10.1007/s00134-023-07208-3. Epub 2023 Sep 12. Intensive Care Med. 2023. PMID: 37698594 Clinical Trial.
After 24 h, 77 (72.8%) and 71 (67.3%) were in sinus rhythm (p = 0.4), restored after a median of 3.7 h (95% CI 2.3-6.8) and 7.3 h (95% CI 5-11), p = 0.02, with propafenone and amiodarone, respectively. The arrhythmia recurred in 54 (52%) patients treated with propafenone a …
After 24 h, 77 (72.8%) and 71 (67.3%) were in sinus rhythm (p = 0.4), restored after a median of 3.7 h (95% CI 2.3-6.8) and 7.3 h (95% CI 5- …
Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial.
Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, Reddy M, Jais P, Themistoclakis S, Dello Russo A, Casella M, Pelargonio G, Narducci ML, Schweikert R, Neuzil P, Sanchez J, Horton R, Beheiry S, Hongo R, Hao S, Rossillo A, Forleo G, Tondo C, Burkhardt JD, Haissaguerre M, Natale A. Di Biase L, et al. Circulation. 2016 Apr 26;133(17):1637-44. doi: 10.1161/CIRCULATIONAHA.115.019406. Epub 2016 Mar 30. Circulation. 2016. PMID: 27029350 Free article. Clinical Trial.
BACKGROUND: Whether catheter ablation (CA) is superior to amiodarone (AMIO) for the treatment of persistent atrial fibrillation (AF) in patients with heart failure is unknown. ...
BACKGROUND: Whether catheter ablation (CA) is superior to amiodarone (AMIO) for the treatment of persistent atrial fibrillation (AF) …
A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation.
Krittayaphong R, Raungrattanaamporn O, Bhuripanyo K, Sriratanasathavorn C, Pooranawattanakul S, Punlee K, Kangkagate C. Krittayaphong R, et al. J Med Assoc Thai. 2003 May;86 Suppl 1:S8-16. J Med Assoc Thai. 2003. PMID: 12866763 Clinical Trial.
The authors randomized 30 patients with chronic atrial fibrillation refractory to medication into amiodarone and radiofrequency ablation. The primary objective of this study was to compare the efficacy of amiodarone and radiofrequency ablation in the maintenance of …
The authors randomized 30 patients with chronic atrial fibrillation refractory to medication into amiodarone and radiofrequency ablat …
Intravenous amiodarone for ventricular arrhythmias: overview and clinical use.
Gonzalez ER, Kannewurf BS, Ornato JP. Gonzalez ER, et al. Resuscitation. 1998 Oct-Nov;39(1-2):33-42. doi: 10.1016/s0300-9572(98)00111-7. Resuscitation. 1998. PMID: 9918445 Review.
Amiodarone's primary mechanism is to prolong the cardiac action potential and repolarization time leading to an increased refractory period and reduced membrane excitability. ...The ARREST trial, a randomized trial comparing IV amiodarone to placebo, found a
Amiodarone's primary mechanism is to prolong the cardiac action potential and repolarization time leading to an increased refr
Survival by time-to-administration of amiodarone, lidocaine, or placebo in shock-refractory out-of-hospital cardiac arrest.
Lupton JR, Neth MR, Sahni R, Jui J, Wittwer L, Newgard CD, Daya MR. Lupton JR, et al. Acad Emerg Med. 2023 Sep;30(9):906-917. doi: 10.1111/acem.14716. Epub 2023 Apr 5. Acad Emerg Med. 2023. PMID: 36869657 Free article. Clinical Trial.
BACKGROUND: Amiodarone and lidocaine have not been shown to have a clear survival benefit compared to placebo for out-of-hospital cardiac arrest (OHCA). ...We sought to evaluate how timing from emergency medical services (EMS) arrival on scene to drug administration affect …
BACKGROUND: Amiodarone and lidocaine have not been shown to have a clear survival benefit compared to placebo for out-of-hospital car …
QT as a predictor of recurrence after atrial fibrillation ablation and the impact of amiodarone: results from the placebo-controlled AMIO-CAT trial.
Diederichsen SZ, Darkner S, Chen X, Johannessen A, Pehrson S, Hansen J, Svendsen JH. Diederichsen SZ, et al. Europace. 2019 Jul 1;21(7):1055-1062. doi: 10.1093/europace/euz028. Europace. 2019. PMID: 30843038 Clinical Trial.
AIMS: Prolonged corrected QT interval (QTc) might be associated with arrhythmia recurrence after atrial fibrillation (AF) ablation. The effect of short-term amiodarone in this setting remains unknown. This study seeks to quantify short-term amiodarone's impac …
AIMS: Prolonged corrected QT interval (QTc) might be associated with arrhythmia recurrence after atrial fibrillation (AF) ablation. The effe …
Clinical efficacy and safety of intravenous Amiodarone in infants and children.
Figa FH, Gow RM, Hamilton RM, Freedom RM. Figa FH, et al. Am J Cardiol. 1994 Sep 15;74(6):573-7. doi: 10.1016/0002-9149(94)90746-3. Am J Cardiol. 1994. PMID: 8074040 Clinical Trial.
The mean loading dose was 5 mg/kg infused over 1 hour, with a starting maintenance dose of 5 micrograms/kg/min. In 18 treatment episodes, amiodarone was used alone or in combination with digoxin. Thirteen patients received amiodarone combined with other antiarrhythm …
The mean loading dose was 5 mg/kg infused over 1 hour, with a starting maintenance dose of 5 micrograms/kg/min. In 18 treatment episodes, …
915 results